CKD患者长期使用阿片类药物与加巴喷丁类药物的危害
这项基于苏格兰东部人群的回顾性队列研究纳入21,440例未使用镇痛药的CKD成人,中位随访4.3年。长期阿片类连续90天处方节段增加与死亡风险升高相关,且呈剂量依赖;长期加巴喷丁类仅在男性中显示死亡风险轻度增加。
要点
- CKD成人长期阿片类连续90天处方节段越多,死亡风险越高。
- 长期加巴喷丁类在男性中死亡风险轻度增加,女性无显著关联。
- 结果支持CKD患者优先采用更安全的疼痛管理策略。
核心结论
- 长期阿片类使用与CKD成人死亡和住院风险增加相关,独立于人口学、合并症和治疗分配偏倚。
研究设计与样本
- 回顾性、时间更新、基于人群的队列研究,数据来自苏格兰东部链接常规收集数据(N=953,542)。
- 纳入2010至2023年生化确认CKD(eGFR<60 ml/min per 1.73 m2)且无肾衰竭的成人。
- 主要暴露为新发长期累积阿片类或加巴喷丁类使用。
- 采用离散时间logistic回归模型、广义估计方程,并调整相关协变量和治疗分配偏倚。
- 30,674例CKD成人进入研究,其中21,440例无现患镇痛药使用纳入主要和次要分析,中位随访4.3年。
主要发现
- 随访期间2,399例患者至少有1个连续90天阿片类处方节段,其中1,159例死亡。
- 连续90天阿片类处方节段从1增至6时,死亡绝对风险从0.4%[0.3-0.4]升至0.6%[0.5-0.7]。
- 连续90天阿片类处方节段为1时OR 1.09[1.06-1.12],P<0.001;为6时OR 1.68[1.41-2.00],P<0.001(参照0)。
- 长期加巴喷丁类在男性中死亡风险可能轻度增加(OR 1.04[1.00-1.08],P=0.050),女性无显著关联(OR 1.02[0.99-1.05],P=0.201)。
临床怎么用
- CKD成人应优先考虑更安全的疼痛管理策略,减少长期阿片类使用。
- 对长期使用加巴喷丁类的CKD患者,尤其是男性,应关注死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Chronic pain affects over half of the patients with chronic kidney disease (CKD). This study aimed to evaluate the association between new long-term opioids or gabapentinoids and the risk of death, hospitalization, and hip fractures in adults with CKD. METHODS: This is a retrospective, time-updated, population-based cohort study from the East of Scotland (N = 953,542) using linked routinely collected data. The study population included adults with biochemically confirmed CKD (estimated glomerular filtration rate [eGFR] <60 ml/min per 1.73 m2) without kidney failure from 2010 to 2023. The primary exposures were new, long-term cumulative opioids or gabapentinoids. Discrete time logistic regression modelling with generalized estimating equations and adjustment for relevant covariates and treatment allocation bias was used to determine the association between chronic analgesic use and all-cause mortality. RESULTS: A total of 30,674 adults with CKD entered the study. Of them, 21,440 patients without prevalent analgesic use were included in the primary and secondary analyses (median follow-up 4.3 years). Among 2399 patients with at least 1 continuous 90-day episode of opioid prescriptions during follow-up, 1159 died. The risk of death increased as continuous 90-day opioid stretches (reference 0) increased from 1 (absolute risk of death: 0.4% [0.3-0.4]; odds ratio [OR]: 1.09 [1.06-1.12], P < 0.001) to 6 (absolute risk of death: 0.6% [0.5-0.7]; OR: 1.68 [1.41-2.00], P < 0.001). Long-term gabapentinoids were potentially associated with a modest increase in death amongst males (OR: 1.04 [1.00-1.08], P = 0.050), but not females (OR: 1.02 [0.99-1.05], P = 0.201). CONCLUSION: Long-term opioid use is associated with increased mortality and hospitalization in adults with CKD independent of demographics, comorbidities, and treatment allocation bias. These findings support prioritization of safer pain management strategies in people with CKD.
引用
- Grant CH, Livingstone S, Wang H, et al. Long-Term Opioid and Gabapentinoid Related Harms in CKD. Kidney Int Rep. 2026. PMID: 42910008. doi:10.1016/j.ekir.2026.107085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。